SEENERGIE
Unleash Human Potential
PT-141
Boosts onset of sexual arousal, heightens libido, and addresses erectile dysfunction and female sexual dysfunction.
Active ingredient:
n/a
Molecular formula:
C50H68N14O10
Molecular weight:
1025.2 g/mol
Intake:
Nasal / Injection
PT-141
Active ingredient:
n/a
Molecular formula:
C50H68N14O10
Molecular weight:
1025.2 g/mol
Intake:
Nasal / Injection
What is
PT-141
Bremelanotide PT-141 was developed from the peptide hormone Melanotan II for aphrodisiac effects. Bremelanotide PT-141 effects sexual function via interaction with the hypothalamus. Its usage has been found to induce rapid onset of arousal. Found to increase erection in 80% of males who did not respond to Viagra or Cialis. Bremelanotide PT-141 has shown to increase chances of women achieving at least one sexually gratifying experience by 50%.
Benefits
- Highens libido
- Produce rapid onset of sexual arousal
- Induces erection in men suffering from ED
- Improve symptoms of female sexual dysfunction
- Improves sexual dysfunction on the level onf central nervous system
Protocols
- Content and Potency
For Nasal Spray
- Provided as a 2.5 mg/spray (0.1 ml)
For Vial
- Provided as a 10mg lyophilized vial
- Suggested Dosage
For Nasal Spray
- Initiation: PT-141 therapy is initiated to enhance sexual desire and arousal by activating melanocortin receptors.
- Initial Dose: Begin with 1 spray (2.5 mg) in each nostril a few hours prior to the desired effect to assess tolerance and minimize potential side effects.
- Titration: If well tolerated, increase the dose to 2-4 sprays (5-10 mg) in each nostril a few hours prior to the desired effect after the initial two-week period.
- Maintenance: Maintain the dose at 1-4 sprays (2.5-10 mg) in each nostril a few hours prior to the desired effect for ongoing support in sexual desire and arousal.
- Duration: PT-141 is administered as needed.
- Weeks 1-2: 1 spray (2.5 mg) in each nostril a few hours prior to the desired effect
- Week 3 and onwards: 1-4 sprays (2.5-10 mg) in each nostril a few hours prior to the desired effect
*Provided as a standard protocol, dose may vary depending on the condition of the patient.
*The dosage of PT-141 may be adjusted based on the individual’s response, medical history, and specific treatment goals.
For Vial
- Initiation: PT-141 therapy is initiated to enhance sexual desire and arousal by activating melanocortin receptors..
- Initial Dose: Begin with 1 mg (0.1 ml or 10 units) subcutaneously up to 3 times per week, 1-2 hours prior to the desired effect for the first two weeks to assess tolerance and minimize potential side effects.
- Titration: If well tolerated, increase the dose to 2 mg (0.2 ml or 20 units) subcutaneously up to 3 times per week, 1-2 hours prior to the desired effect after the initial two-week period.
- Maintenance: Maintain the dose at 1-2 mg (0.1-0.2 ml or 10-20 units) subcutaneously up to 3 times per week for ongoing support in sexual desire and arousal.
- Duration: PT-141 is administered as needed, up to three times per week.
- Weeks 1-2: 1 mg (0.1 ml or 10 units) of PT-141 subcutaneously up to 3 times per week
- Week 3 and onwards: 1-2 mg (0.1-0.2 ml or 10-20 units) of PT-141 subcutaneously up to 3 times per week
*Provided as a standard protocol, dose may vary depending on the condition of the patient.
*The dosage of PT-141 may be adjusted based on the individual’s response, medical history, and specific treatment goals.
- Restrictions
- Known hypersensitivity to PT-141 or any component of the formulation.
- Not recommended for use during pregnancy or breastfeeding unless specifically advised by a healthcare provider.
- Patients with cardiovascular conditions should consult with their healthcare provider before starting this treatment.
- Avoid using other medications or supplements that might interact with PT-141 without professional advice.
- Requirements
- Regular monitoring of response to the treatment to assess effectiveness.
- Periodic assessments to check for any adverse effects and to adjust the treatment as necessary.
- Consultation with a healthcare professional before starting PT-141 to ensure it is appropriate for the patient’s health condition.
- Patients should maintain a healthy lifestyle to support the effectiveness of the treatment.
Procedure
- PT-141
Reconstitution
- Draw 1 ml of sterile water for injection into a syringe.
- Inject the sterile water into a vial containing 10 mg of PT-141 peptide.
- Gently swirl the vial until the peptide is fully dissolved.
- Administration
For Nasal Spray
- Shake the nasal spray bottle gently before use.
- Remove the cap from the nasal spray bottle.
- Insert the nozzle into one nostril and close the other nostril with a finger.
- Press down on the pump to release 1 spray (2.5 mg) while inhaling gently through the nose.
- Repeat the process for the other nostril.
- Administer 1-4 sprays in each nostril a few hours prior to the desired effect, as needed.
- Do not exceed the recommended dosage unless advised by a healthcare provider.
For Vial
- Remove the cap from a tuberculin syringe.
- Draw the reconstituted PT-141 solution into the syringe to the required dosage (0.1 ml or 10 units initially, 0.2 ml or 20 units after titration).
- Clean the selected injection site with an alcohol swab.
- Pinch the sanitized skin and insert the needle at a 90-degree angle.
- Administer the injection subcutaneously 1-2 hours prior to the desired effect.
- For next usage
For Nasal Spray
- Store the nasal spray bottle in a cool, dry place away from direct sunlight.
- Ensure the bottle is tightly sealed to maintain the integrity of the solution.
- Keep out of reach of children.
- Monitor for any unusual symptoms and report them to a healthcare provider immediately.
For Vial
- Store the remaining PT-141 solution in the refrigerator at 2-8°C.
- Before the next use, clean the vial top with an alcohol swab.
- Use a new syringe for each subcutaneous administration.
- Ensure to rotate injection sites (abdomen, thigh, or upper arm) to minimize skin irritation.
- Monitor for any unusual symptoms and report them to a healthcare provider immediately.
Clinical Research
Study:
PT-141 for Sexual Arousal and Dysfunction
Source:
Cochrane Handbook, Peptides.org, Pro Peptide Source
Results:
PT-141, also known as Bremelanotide, is a synthetic peptide derived from the melanocortin-stimulating hormone. It has been extensively studied for its ability to treat sexual arousal disorders in both men and women. The peptide is primarily administered via subcutaneous injection and has shown promising results in increasing sexual desire and arousal.
PT-141 acts as an agonist of melanocortin receptors, particularly MC4R, which are involved in the regulation of sexual behavior. By stimulating these receptors, PT-141 enhances sexual desire and arousal by activating neural pathways in the brain that are responsible for these functions. Unlike other treatments for sexual dysfunction, PT-141 does not affect the vascular system directly but instead works centrally to modulate sexual desire.
Clinical trials have shown that PT-141 is effective in treating HSDD in premenopausal women. The peptide significantly increased sexual desire and reduced distress associated with low sexual desire. PT-141 has been studied as an alternative treatment for erectile dysfunction, particularly in patients who do not respond to phosphodiesterase type 5 inhibitors like sildenafil (Viagra). Studies demonstrated that PT-141 could induce erections in men with erectile dysfunction by enhancing sexual arousal.Both men and women reported improved sexual satisfaction and increased frequency of sexual activity after using PT-141.
Cochrane Handbook, 2023; Peptides.org, 2023; Pro Peptide Source, 2023.
Read More: https://www.cochrane-handbook.org, https://www.peptides.org, https://www.propeptidesource.com
Articles
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScan™ in healthy subjects without visual sexual stimulation (VSS) and in Viagra®-responsive ED patients with VSS. In healthy subjects, mean Cmax and AUC(0–t) increased in a dose-dependent manner. […]
Bremelanotide for Treatment of Female Hypoactive Sexual Desire
Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this disorder may display a lack of motivation for sexual activity, reduced responsiveness to erotic cues, a loss of interest during sexual activity, and avoidance of situations that could lead […]
Doctor's Reviews
Does Bremelanotide or PT-141 actually Work to Increase Sexual Desire?!
Have you heard of Bremelanotide or PT-141? Does it work for premenopausal women only? Or is this amazing new drug a new option for erectile dysfunction and low libido for men?
Melanotan 2 – Tan & Sex Addiction & PT-141 – Doctor’s Analysis
Melanotan II is a tanning injection, never approved for use by any health agency. It is a non-selective melanocyte stimulant, which also seems to enter the central nervous system where it increases libido and causes spontaneous erections in men.
Why Is PT-141 So Popular? | Sexual Performance Peptides
PT-141 is a peptide that can be used to enhance the sexual experience for both men and women.
